Application due date December 20, 2022.
This Funding Opportunity Announcement invites multiple Program Director/Principal Investigator (multi-PD/PI) applications to conduct a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID-19 diabetes. The cohort must include children and adults and reflect the geography and demographics of COVID-19 in the U.S. There must be an appropriate comparator population recruited and followed. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy.
Topics: Clinical Presentation of Infection, ARDS, Cellular / Molecular Response, Inflammation, Long-term Impact of Infection, Pneumonia, Sensory, Clinical Trial, Co-Morbidities, COVID-19, Diabetes, Epidemiology, Clinical History, Clinical Outcome, Contact Tracing, Incidence, Risk Factors, Surveillance, Transmission, Aerosol, Health Disparities, Immunity, Immunology, Host Factors, Host Response, Mental Health, Psychology, Organ, Brain, Endocrine, Eye, Heart, Kidney, Research Site, Community-based, Virology, Viral Interactome, Viral Proteins, Virus Biology, Virus Evolution, Virus Factors, Vaccine Development, Vaccine Efficacy, Vaccine Reliability, Vaccine Scalability, Research Tool Development, Social Determinants of Health, Target Population, Children, Elderly, Pregnant Women, Teens, Treatments, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Drugs, Antibody-based Treatment, Convalescent Serum, Drug Development